The Top 15 R&D Budgets
In the world of drug development, you're only as good as your pipeline. As many companies' older blockbuster drugs go off-patent, analysts are looking at pipelines to see who'll have what it takes to survive and grow, and which companies will fall behind in the race to develop new drugs.
A recent EU report ranked the world's largest R&D budgets, and Pfizer took the lead--not just among drug developers but among all industries--with a staggering $8.34 billion budget in 2006. But as this report shows, spending more money doesn't necessarily make for a better pipeline. Take a look at this list of the top 15 pharmaceutical R&D budgets to find out how they're spending all those billions of dollars, who's keeping their edge, and who's falling behind.
1. Pfizer
5. Roche
6. Novartis
7. Merck
8. AstraZeneca
9. Amgen
10. Bayer
11. Eli Lilly
12. Wyeth
14. Abbott
15. Schering-Plough
Vote for your favorite pipeline
Comments
By Anonymous | Posted 1:40am | November 30, 2007
So let's see a list that means something. I know it is very subjective, but who has the "best" pipeline? Perhaps not rated 1-10, but grouped by winners, losers, and those still in the game. It's not to hard to assume the largest company spends the most money. Who is using their research dollar more successfully? Is that something you can report on?
By maureen | Posted 9:19am | November 30, 2007
In doing this research there were definitly pipelines that impressed me (and industry analysts) more than others, but I prefer to present the fact based on publicly available data and let readers draw their own conclusions.
As for how well these companies are spending their money, it's tough to say. Schering-Plough, for instance, has the smallest budget on this list, yet analysts generally regard its pipeline as one of the strongest in pharma. Pfizer spends the most money yet industry experts spend a lot of time fretting over whether or not the company has what it takes to cut it in the future. But Pfizer's made some huge investments in biotech this year that will take a while to develop but could really make a difference in the future. So is their $8+ billion budget well spent? It will be a while before we know.
By ingenious_kitty | Posted 1:26pm | December 4, 2007
Hi All,
Please lets not forget that the “budgets” are educe by capable companies with revenues way above commons and the “analytical scales” of the pros are not that same as of the “field members” money makes a whole lot of difference. But I prefer the basic lines of reports very interesting comment (by: Maureen) I think we are meant to analyze the facts ourselves and acknowledge perfection comes with time and capable funds :)
By Charlie Masterson | Posted 12:32pm | December 12, 2007
What about Elan, if you read the trade mag they have the best drugs on the market now (the next best substitute for Morphine for pain and Tysbiri for MS (possible other indications but awaiting FDA approval))and the best pipeline for Alz & Park. phase 2 & 3.
By Prialt Disaster | Posted 2:21pm | October 31, 2008
If you are referring to Prialt as the best substitute for Morphine...I disagree. It is easily overdosed in the elderly and has no guidelines for treatment of the disease process thereof.
SHARE
WITH: